Revised SPC: ZYTIGA (abiraterone) 500 mg film-coated tablets -

Revised SPC: ZYTIGA (abiraterone) 500 mg film-coated tablets
Information type: Drug prescribing
Source: electronic Medicines compendium
Specialities: Cancers | Musculo-skeletal disorders | Renal and urologic disorders
Summary
SPC now warns that treatment with abiraterone and prednisone/prednisolone in combination with Ra-223 is contraindicated due to an increased risk of fractures and trend for increased mortality among asymptomatic/mildly symptomatic patients as observed in clinical trials.
UKMi comment
Subsequent treatment with Ra-223 should not be initiated for at least 5 days after last administration of abiraterone and prednisone/prednisolone.
Related links: